Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

Abbott will acquire Exact Sciences for $105 per share—approximately $21 billion in equity value and roughly $23 billion enterprise value including about $1.8 billion of net debt—with closing expected in Q2 2026 subject to shareholder and regulatory approval and unanimous board support. The deal brings Exact’s market-leading cancer diagnostics (Cologuard, Oncotype DX, Cancerguard, Oncodetect) into Abbott, immediately accretes to Abbott’s revenue growth and gross margin, boosts Abbott’s diagnostics sales to over $12 billion and establishes leadership in the fast-growing U.S. cancer screening and precision oncology market (estimated ~$60 billion), with Exact forecasting >$3 billion in revenue and high-teens organic growth. Financing includes fully committed debt from Morgan Stanley; integration, regulatory clearance and shareholder approval remain key execution risks.

Analysis

Abbott Laboratories announced a definitive agreement to acquire Exact Sciences for $105 per share, implying approximately $21 billion of equity value and an estimated $23 billion enterprise value including about $1.8 billion of net debt, with closing expected in Q2 2026 subject to Exact Sciences shareholder approval and regulatory clearances. The boards of both companies unanimously approved the transaction and Abbott stated the deal will be immediately accretive to revenue growth and gross margin; a special investor call is scheduled for today.

The acquisition brings Exact Sciences' established products—Cologuard, Oncotype DX, Cancerguard and Oncodetect—and a next-generation diagnostics pipeline into Abbott, enlarging Abbott's diagnostics sales to more than $12 billion annually. Exact Sciences projects more than $3 billion in revenue this year with high‑teens organic sales growth, positioning Abbott to enter an estimated $60 billion U.S. cancer screening and precision oncology diagnostics market.

Financing is supported by fully committed debt from Morgan Stanley, but key execution risks include regulatory approval, shareholder vote, integration execution, potential diversion of management attention and customary termination/transaction costs. Abbott will retain Exact's Madison operations and Exact's CEO will remain in an advisory role, which should support continuity during integration but does not eliminate regulatory or realization risks.

Key Decisions for Investors

• Consider adding exposure to Abbott on strategic rationale and immediate accretion, but size positions conservatively until shareholder and regulatory approvals and an integration plan are public
• Exact Sciences shareholders should weigh the certain $105 cash consideration against projected standalone growth (> $3 billion revenue, high‑teens organic growth) when deciding how to vote
• Monitor the proxy filing, regulatory milestones, and integration KPIs closely and use hedges (e.g., options or position size limits) to protect against deal failure or execution risk